Quidel Corp
Open
13.47 10.96
Übersicht
Veränderung der Aktienkurses
24h
Min
12.14
Max
13.52
Einkommen | 39M -92M |
|---|---|
Verkäufe | -104M 620M |
Gewinnspanne | -14.811 |
Angestellte | 6,500 |
Empfehlungen | Sell |
|---|---|
12-Monats-Prognose | +22.15% upside |
Nächstes Ergebnis | 4. Nov. 2026 |
|---|
Marktkapitalisierung | 282M 983M |
|---|---|
Vorheriger Eröffnungskurs | 2.51 |
Vorheriger Schlusskurs | 13.47 |
Quidel Corp Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Quidel Corp Prognose
Kursziel
By TipRanks
22.15% Vorteil
12-Monats-Prognose
Durchschnitt 15 USD 22.15%
Hoch 18 USD
Tief 12 USD
Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Quidel Corp – Dist angeboten haben.
Finanzen
Vertriebs- und Verwaltungskosten
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
Betriebsergebnis
$
Über Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
